SS-31 (Elamipretide)

✓Key benefits

📈What to expect

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Overview

SS-31 was developed by Hazel Szeto and Peter Bhatt at Weill Cornell Medical College as part of a series of Szeto-Schiller (SS) peptides designed to target mitochondria. Unlike most antioxidants that fail to reach mitochondria in meaningful concentrations, SS-31 concentrates over 5,000-fold in the inner mitochondrial membrane within minutes of administration. It binds selectively to cardiolipin - a phospholipid unique to the inner mitochondrial membrane that is essential for electron transport chain (ETC) function. Clinical trials have been conducted for Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related macular degeneration under the names elamipretide and Bendavia.

⚙️How it works

SS-31 penetrates cell membranes due to its alternating aromatic-cationic motif (positively charged amino acids alternating with aromatic residues). It accumulates in the inner mitochondrial membrane driven by the mitochondrial membrane potential. There, it binds to cardiolipin and stabilises its interaction with cytochrome c, preventing cytochrome c from acting as a peroxidase (which generates ROS) and maintaining its electron carrier function. This restores ETC efficiency, reduces electron leak and ROS production, and improves ATP synthesis. The net effect is improved mitochondrial function without acting as a conventional antioxidant.

⚡Side effects

📅Research history

The cardiolipin hypothesis of aging

Cardiolipin is a phospholipid found exclusively in the inner mitochondrial membrane, where it constitutes approximately 20% of total lipid content. It is essential for the structural integrity of electron transport chain complexes and for cytochrome c function. With age, cardiolipin content decreases and its fatty acid composition changes (less linoleic acid), leading to reduced ETC efficiency, increased electron leak, higher ROS production, and lower ATP output. SS-31's ability to stabilise cardiolipin and restore ETC function addresses what some researchers consider a fundamental mechanism of cellular aging.

Clinical trial landscape

SS-31 has been tested in multiple Phase II and Phase III trials. The TAZPOWER trial in Barth syndrome (a genetic cardiolipin deficiency) showed improvements in the 6-minute walk test. Trials in primary mitochondrial myopathy (MMPOWER) showed mixed results - the primary endpoint was not met but subgroup analyses were encouraging. Heart failure trials (EMBRACE STEMI) demonstrated improved cardiac function after myocardial infarction. A trial in age-related macular degeneration (ReCLAIM) showed reduced drusen volume. While not all trials have met primary endpoints, the consistent signal across multiple organ systems supports the cardiolipin mechanism.

References

1. [1]Szeto HH. 'First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.' British Journal of Pharmacology, 2014.
2. [2]Karaa A, et al. 'Randomised dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.' Neurology, 2018.

Frequently asked questions

Related peptides